The legacy of Viagra, and its developer copyright, presents a intriguing case study for investors. Initially a blockbuster drug, generating billions in sales , its intellectual property lapse created a flood of knock-off medications, significantly eroding its dominance. While specific firms may attempt to capitalize on similar conditions , the curr